SCHEMBL2115618

SCHEMBL2115618

Cc1[nH]c(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4cccc(Cl)c4)cc32)c(C)c1C(=O)NCCN1CCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.66
PDGFRB P09619 8/20 0.66
FGFR1 P11362 8/20 0.66
TLK2 Q86UE8 2/20 0.66
KIT P10721 3/20 0.55
EGFR P00533 2/20 0.55
NEK2 P51955 2/20 0.55
MELK Q14680 1/20 0.55
MET P08581 6/20 0.54
FLT3 P36888 5/20 0.54
AURKB Q96GD4 3/20 0.54
MEN1 O00255 2/20 0.54
CDK2 P24941 2/20 0.54
KMT2A Q03164 2/20 0.54
PTK2B Q14289 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
CCNE1 P24864 1/20 0.54
RECQL P46063 1/20 0.54
PRKAA2 P54646 5/20 0.52
PRKAA1 Q13131 5/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13755234 1.00 KDR (0.66) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL6427814 0.88 KDR (0.65) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL2116509 0.88 KDR (0.65) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL142633 0.88 KDR (0.66) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL6082409 0.87 KDR (0.74) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL31672505 0.87 KDR (0.74) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL2116563 0.87 KDR (0.74) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL13755252 0.86 KDR (0.81) KDRPDGFRBFGFR1TLK2KIT
SCHEMBL4474309 0.85 ALK (0.58) KDRPDGFRBFGFR1KITEGFR
SCHEMBL3720888 0.85 ALK (0.58) KDRPDGFRBFGFR1KITEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094998-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates PTK2B, ERBB2, FRK KDR 395/4885PDGFRB 555/4885FGFR1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.